Skip to main content

Assisted Reproductive Technology Market Set to Soar Past USD 12272.5 Million by 2030

The global Assisted Reproductive Technology market size is expected to reach USD 12272.5 million by 2030 and exhibit a CAGR of 19.3% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing prevalence of infertility, growing awareness and acceptance of assisted reproductive technologies, advancements in reproductive technology and techniques, expanding medical tourism for fertility treatments, rising demand for donor eggs and sperm, and improving success rates of assisted reproductive procedures are fueling the Market’s growth.

Westford USA, Oct. 18, 2023 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Assisted Reproductive Technology market, increasing utilization of advanced reproductive technologies such as in vitro fertilization (IVF), growing demand for personalized and tailored fertility treatments, rise in the use of third-party reproduction methods like egg and sperm donation, adoption of genetic screening and preimplantation genetic testing (PGT), advancements in cryopreservation techniques for egg, sperm, and embryo freezing, expanding use of assisted reproductive technologies for fertility preservation, are the trends that aid in the market’s growth.

Browse in-depth TOC on “Assisted Reproductive Technology Market”

  • Pages – 165
  • Tables – 91
  • Figures – 76

Assisted reproductive technology (ART) is a broad term that encompasses any medical procedure that helps a person or couple conceive a child. ART techniques involve the manipulation of eggs, sperm, or embryos to increase the likelihood of a successful pregnancy.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/assisted-reproductive-technology-market

Prominent Players in Assisted Reproductive Technology Market

  • Vitrolife
  • CooperSurgical
  • EMD Serono
  • Irvine Scientific
  • Igenomix
  • Cook Medical
  • Ferring Pharmaceuticals
  • Origin Medsystems
  • SAGE Pharmaceuticals
  • Andrology Solutions
  • Procrea Biosciences
  • Genea Limited
  • Monash IVF
  • INVO Bioscience
  • Extend Fertility
  • IVIRMA
  • Genesis Genetics
  • HRA Pharma
  • IBSA Lifesciences
  • Theratechnologies
  • OXGENE

In Vitro Fertilization Demand to Grow Substantially in the Forecast Period

In vitro fertilization dominated the global market owing to its high success rate. It is a versatile procedure that can be utilized in various fertility scenarios. It can be used to overcome various causes of infertility, including tubal factor infertility, male factor infertility, advanced maternal age, and unexplained infertility. IVF can also be combined with other techniques such as preimplantation genetic testing (PGT), to screen embryos for genetic disorders or select embryos of a desired gender.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/assisted-reproductive-technology-market

Infertility is the Leading Application Segment

In terms of application, infertility is the leading segment due to the prevalence of infertility. In addition, the strong desire for parenthood among individuals and couples facing infertility issues is a powerful driver for the assisted reproductive technology market. Assisted reproductive technology offers hope and an opportunity for these individuals and couples to fulfil their dream of having children. The emotional significance attached to parenthood motivates them to seek fertility treatments, resulting in increased sales for the market.

North America is the leading Market Due to the Developed Health Infrastructure

Region-wise, North America is the largest market with a huge emphasis on healthcare infrastructure. The region has a higher level of awareness and acceptance of assisted reproductive technology among the general population compared to other regions. There is greater familiarity with fertility treatments and a more open attitude towards seeking assistance for infertility. This cultural mindset leads to a higher demand for assisted reproductive technology services in the region.

A recent report thoroughly analyzes the major players operating within the Assisted Reproductive Technology market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavors to develop innovative solutions that cater to the ever-increasing demand for Assisted Reproductive Technology.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/assisted-reproductive-technology-market

Key Developments in Assisted Reproductive Technology Market

  • Inception Fertility expanded its ecosystem with the launch of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that provides a one-of-a-kind experience for fertility doctors and patients. It includes assisted reproductive techniques (ART).

Key Questions Answered in Assisted Reproductive Technology Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Bionic Eye Market

Cold Plasma Market

Fill Finish Manufacturing Market

Hemoglobinopathies Treatment Market

CRISPR Technology Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.